Daiichi Sankyo Company, Limited

4568.T
Drug Manufacturers - General
2026/03/06 Updated
Market Cap: $33.5B (¥5.3T)
Stock Price: $18.09 (¥2,844)
Exchange Rate: 1 USD = ¥157.23

Notice Regarding Status of Treasury Stock Acquisition

From February 1 to February 28, 2026, the Company acquired 14,198,900 shares of common stock for ¥41,849,992,950. The total cumulative shares acquired amount to 17,602,500 shares, with an acquisition cost of ¥51,849,239,900.

Importance:
Page Updated: March 2, 2026
IR Disclosure Date: March 2, 2026

Key Figures

  • Total Number of Shares Acquired: 14,198,900 shares (February 1, 2026 to February 28, 2026)
  • Total Acquisition Cost of Shares: ¥41,849,992,950 (February 1, 2026 to February 28, 2026)
  • Cumulative Number of Shares Acquired: 17,602,500 shares (as of February 28, 2026)

AI要約

Overview of Treasury Stock Acquisition

Daiichi Sankyo Company, Limited acquired 14,198,900 shares of its common stock for ¥41,849,992,950 during the period from February 1 to February 28, 2026, based on the provision of Article 165, Paragraph 2 of the Companies Act. The acquisition method was market purchase on the Tokyo Stock Exchange.

Cumulative Acquisition Status and Future Outlook

Based on the Board of Directors resolution on April 25, 2025, the Company is conducting treasury stock acquisitions within a maximum of 80 million shares and an upper limit acquisition cost of ¥200 billion during the period from May 1, 2025 to March 24, 2026. As of February 28, 2026, the cumulative number of shares acquired is 17,602,500 shares and the acquisition cost is ¥51,849,239,900.

This page uses AI to summarize IR materials from TDnet. Please refer to the original document for investment decisions.